BEAM [high-dose carmustine, etoposide, cytarabine, and melphalan] Plus Iodine-131 Anti-B1 Antibody [iodine-131 tositumomab], and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma.

Trial Profile

BEAM [high-dose carmustine, etoposide, cytarabine, and melphalan] Plus Iodine-131 Anti-B1 Antibody [iodine-131 tositumomab], and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 01 Nov 2010 Planned End Date (Jan 2015) added as reported by ClinicalTrials.gov.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top